Pathogenic genomic alterations in Chinese pancreatic cancer patients and their therapeutical implications

BACKGROUND: Approximately 90% of pancreatic ductal adenocarcinoma (PDAC) cases are driven by the untargetable non‐G12C KRAS mutations, and only a small subset of patients are eligible for FDA‐approved precision therapies. The practice of precision therapy in pancreatic cancer was limited by the pauc...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Zhiming, Li, Xiaomo, Wang, Fei, Xu, Yong, Liu, Si, Han, Quanli, Yang, Zhiying, Huang, Weiwei, Yin, Zhuzeng, Liu, Qu, Tan, Haidong, Ma, Tonghui, Si, Shuang, Huang, Jia, Yuan, Hongling, Li, Wei, Liu, Rong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10242355/
https://www.ncbi.nlm.nih.gov/pubmed/36999792
http://dx.doi.org/10.1002/cam4.5871

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10242355/
https://www.ncbi.nlm.nih.gov/pubmed/36999792
http://dx.doi.org/10.1002/cam4.5871

Ejemplares similares